Haematological Malignancies Journal Articles and Videos
An Exciting New Era in the Treatment of Myeloproliferative Neoplasms
Oncology & Hematology Review, 2016;12(2):71–4 DOI: https://doi.org/10.17925/OHR.2016.12.02.71
Measurable (Minimal) Residual Disease—A Meaningful Biomarker in Multiple Myeloma
Oncology & Hematology Review, 2016;12(2):75–6 DOI: https://doi.org/10.17925/OHR.2016.12.02.75
Myelodysplastic Syndromes – Just a Matter of Age?
Oncology & Hematology Review, 2016;12(1):20–1 DOI: http://doi.org/10.17925/OHR.2016.12.01.20
Individualized Treatment of Diffuse Large B-cell Lymphoma— The Evolving Role of Molecular-subtype-specific Therapy
Oncology & Hematology Review, 2015;11(2):113–4 DOI: http://doi.org/10.17925/OHR.2015.11.02.113
University of Texas MD Anderson Cancer Center
Dr. Elias Jabbour graduated from the Saint Joseph’s School of Medicine in 1998 and joined, thereafter, the Hotel Dieu de France University Hospital as a resident. In 2001, he pursued in fellowship in Hematology-Oncology at the Gustave Roussy Institute. In 2003, he joined the University of Texas M. D. Anderson Cancer as a fellow in the Department of Hematology/Leukemia and Stem cell transplantation. Thereafter, in 2007, he joined the faculty in the Leukemia department as Assistant Professor. Dr. Jabbour is actively involved in research in both acute and chronic forms of leukemia. He was actively involved in clinical trials that lead to the approval of several drugs in chronic myeloid leukemia (CML) and myelodysplastic syndromes. His research on resistance to imatinib and mutations of the protein kinase domain were presented in several international; meetings and published in peer-reviewed journals. He is also developing tailored therapies to CML.
Head, Institute of Hematology and Medical Oncology, “L and A Sercignoli”, S Orsala University Hospital, Professor of Hematology, University of Bologna
Prof. Baccarani is Chairman of the Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) chronic myeloid leukaemia (CML) Working Party (formerly the Italian Cooperative Study Group on CML) and of the CML working group of the European LeukemiaNet.
Prof. Baccarani is the first or contributing author on over 600 publications in the field of haematology.
Previously, he was Professor of Haematology at the University of Bologna and Head of the Department of Haematology and Oncology ‘L and A Seràgnoli’ at the S Orsola-Malpighi University Hospital, Bologna until November 2012. He headed the Division of Haematology and Bone Marrow Transplantation of Udine University Hospital during his post as a Professor of Haematology at Udine University. He has also held faculty positions as a Professor of Haematology at Trieste University and of Cancer Chemotherapy at Chieti University.
He is Past President of both the Italian Society of Haematology and the Italian Society of Experimental Haematology